Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted) (2019 - 2025)

Arcus Biosciences (RCUS) has 7 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.18 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$1.18; the TTM value through Dec 2025 reached -$3.32, changed N/A, while the annual FY2025 figure was -$3.29, 4.78% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.18 in Q4 2025 per RCUS's latest filing, down from -$1.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.99 in Q4 2021 and bottomed at -$1.18 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.62, with a median of -$1.0 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 558.62% in 2021, down 3800.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.99 in 2021, then plummeted by 123.06% to -$0.92 in 2022, then dropped by 17.39% to -$1.08 in 2023, then rose by 7.41% to -$1.0 in 2024, then decreased by 18.0% to -$1.18 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.18 in Q4 2025, -$1.14 in Q1 2025, and -$1.0 in Q3 2024.